Core Insights - Elicio Therapeutics, a clinical-stage biotechnology company, is advancing a pipeline of novel immunotherapies for cancer treatment and has announced upcoming presentations at key conferences in September and October 2024 [1][6]. Presentation Details - The first presentation will be at the AACR Special Conference on Advances in Pancreatic Cancer Research from September 15-18, 2024, featuring Dr. Eileen O'Reilly discussing recent Phase I AMPLIFY-7P trial updates [2][3]. - The second presentation will occur at the RAS-Targeted Drug Development Summit on September 25, 2024, where Dr. Pete DeMuth will present on the clinical translation of Elicio's RAS-targeted Amphiphile vaccines [3][4]. - The third presentation is scheduled for the Advances in Cancer Vaccines Summit on October 1, 2024, with Dr. Christopher Haqq discussing Phase I experiences with ELI-002 2P and ELI-002 7P [4][5]. Financial and Clinical Updates - Elicio has raised $43 million in funding in 2024, which is expected to support operations into the second quarter of 2025 [5]. - The company anticipates providing additional clinical data updates from the AMPLIFY-201 trial in the fourth quarter of 2024 and interim analysis from the AMPLIFY-7P randomized Phase 2 trial in the first quarter of 2025 [5]. Company Overview - Elicio Therapeutics focuses on developing lymph node-targeted immunotherapies for aggressive cancers, utilizing its proprietary AMP technology to enhance the immune system's cancer-fighting capabilities [6][8]. - The AMP platform is designed to deliver immunotherapeutics directly to lymph nodes, aiming to optimize the immune response against tumors [8][10]. - Elicio's R&D pipeline includes therapeutic cancer vaccines targeting mKRAS-driven cancers (ELI-002) and other mutations [7][9].
Elicio Therapeutics Announces Three Upcoming Presentations Focused on its Lymph Node Targeted, mKRAS-Specific Amphiphile Vaccines